Stockscreener 앱 받기
13.01
11.29%
1.32
전일 마감가:
$11.69
열려 있는:
$11.48
하루 거래량:
5.97M
Relative Volume:
1.74
시가총액:
$1.75B
수익:
$24.30M
순이익/손실:
$-145.57M
주가수익비율:
-9.782
EPS:
-1.33
순현금흐름:
$-149.17M
1주 성능:
+10.72%
1개월 성능:
+45.20%
6개월 성능:
+104.88%
1년 성능:
+367.99%
1일 변동 폭
$11.33
$13.18
1주일 범위
$9.99
$13.18
52주 변동 폭
$1.03
$13.18
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
TNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
13.01 | 1.57B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Tango Therapeutics stock hits 52-week high at 12.65 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics stock hits 52-week high at 12.65 USD - Investing.com India
TNGX Analyst Rating Update: Piper Sandler Raises Price Target | TNGX Stock News - GuruFocus
Tango Therapeutics (NASDAQ:TNGX) Sets New 52-Week HighHere's Why - MarketBeat
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Nasdaq Futures Research-Driven Model - Kalkine Media
TNGX: Leadership shift supports late-stage trials and robust MTAP-deleted cancer pipeline progress - TradingView — Track All Markets
Tango Therapeutics (NASDAQ:TNGX) Trading 8.3% HigherShould You Buy? - MarketBeat
TNGX: Smooth leadership transition supports late-stage trials in MTAP-deleted cancers and robust 2026 milestones - TradingView — Track All Markets
Sentiment Review: Will Tango Therapeutics Inc stock recover after earningsEntry Point & Intraday High Probability Alerts - baoquankhu1.vn
Tango Therapeutics (NASDAQ:TNGX) Stock Price Down 8.4%What's Next? - MarketBeat
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data - Investing.com Canada
Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data By Investing.com - Investing.com India
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 29% - 富途牛牛
Does Tango Therapeutics’ (TNGX) CEO Transition Clarify or Complicate Its Precision Oncology Roadmap? - Yahoo Finance
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor - Sahm
Can Tango Therapeutics Inc. stock sustain market leadershipJuly 2025 Macro Moves & Weekly Return Optimization Plans - Улправда
How Tango Therapeutics Inc. stock reacts to oil prices2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Tango Therapeutics Appoints Dr. Malte Peters as CEO - citybiz
Can Tango Therapeutics Inc. stock resist market sell offsJuly 2025 Macro Moves & Safe Capital Growth Plans - Улправда
Will Tango Therapeutics Inc. stock deliver long term returnsTrade Exit Summary & Daily Price Action Insights - Улправда
Tango Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 8, 2026 - marketscreener.com
Tango Therapeutics' CEO Retires, Successor Appointed; Shares Fall - MarketScreener
Is Tango Therapeutics Inc. stock a defensive play in 2025Dip Buying & Short-Term High Return Ideas - Улправда
Tango Therapeutics announces CEO transition: Barbara Weber to retire, Malte Peters appointed successor - marketscreener.com
Tango Therapeutics appoints Malte Peters as new CEO By Investing.com - Investing.com Australia
Tango Therapeutics appoints new CEO amid leadership transition - TipRanks
Tango Therapeutics appoints Malte Peters as new CEO - Investing.com
Tango Therapeutics Announces Leadership Transition: Barbara Weber, M.D. Becomes Executive Chair as Malte Peters, M.D. Assumes Role of President and CEO - Quiver Quantitative
Tango Therapeutics stock hits 52-week high at $11.21 By Investing.com - Investing.com Nigeria
Tango Therapeutics (NASDAQ:TNGX) Sets New 12-Month HighHere's What Happened - MarketBeat
Tango Therapeutics stock hits 52-week high at $11.21 - Investing.com
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.4%Here's What Happened - MarketBeat
Tango Therapeutics appoints Sung Lee to board of directors By Investing.com - Investing.com Nigeria
Tango Therapeutics adds independent director to strengthen governance - MSN
Tango Therapeutics Adds Independent Director to Strengthen Governance - TipRanks
Tango Therapeutics appoints Sung Lee to board of directors - Investing.com
Tango Therapeutics Appoints Sung Lee to Board of Directors - The Manila Times
Hindware Home Innovation Limited Reaches Critical Trendline SupportStraddle and Strangle Trades & Low Risk Investment Plans - earlytimes.in
Tango Therapeutics (NASDAQ:TNGX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Tango Therapeutics Advances TNG462 Study for MTAP-deleted Tumors - MSN
Patterns Watch: How Tango Therapeutics Inc stock reacts to oil pricesDip Buying & Safe Entry Point Identification - moha.gov.vn
Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why - MSN
3 Stocks With Strong Upside Potential for 2026 Gains - Tokenist
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026 - Investing.com
Certain Common Stock of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
Certain Pre-Funded Warrants of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2025. - marketscreener.com
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - WV News
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Tango Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Sentiment & Fast Entry High Yield Tips - Улправда
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):